- Despite its recent share price increase, Evogene continues to be undervalued given the sum of parts valuation of its 4 main subsidiaries and $45 million cash position.
- Evogene is a computational biology company. This article is Part 4 of a 4 part series which will focus on Evogene's wholly-owned subsidiary Canonic Ltd. (medical cannabis).
- Canonic has Israel's largest Cannabis R&D facility, is fully licensed, and has a state of the art 22,000 square foot greenhouse and molecular labs.
- Canonic has entered into agreements with multiple potential partners and anticipates commercial sales to begin in 2022 first in Israel and then Europe, followed by the US in 2023.
For further details see:
Evogene: Hidden Gems Of Computational Predictive Biology: (Part 4 Of 4), Canonic Ltd. (Medical Cannabis)